Gossamer Bio, Inc. (GOSS)
11.17
-0.26
(-2.27%)
USD |
NASDAQ |
Nov 19, 16:00
11.17
0.00 (0.00%)
After-Hours: 20:00
Gossamer Bio Enterprise Value : 59.57M for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 59.57M |
| November 17, 2026 | 57.19M |
| November 16, 2026 | 56.82M |
| November 13, 2026 | 56.76M |
| November 12, 2026 | 58.41M |
| November 11, 2026 | 61.16M |
| November 10, 2026 | 58.66M |
| November 09, 2026 | 54.77M |
| November 06, 2026 | 49.42M |
| November 05, 2026 | 47.28M |
| November 04, 2026 | 50.52M |
| November 03, 2026 | 46.42M |
| November 02, 2026 | 47.46M |
| October 30, 2026 | 53.15M |
| October 29, 2026 | 55.05M |
| October 28, 2026 | 55.05M |
| October 27, 2026 | 49.42M |
| October 26, 2026 | 45.63M |
| October 23, 2026 | 48.41M |
| October 22, 2026 | 47.52M |
| October 21, 2026 | 49.54M |
| October 20, 2026 | 48.26M |
| October 19, 2026 | 41.22M |
| October 16, 2026 | 43.30M |
| October 15, 2026 | 44.04M |
| Date | Value |
|---|---|
| October 14, 2026 | 44.13M |
| October 13, 2026 | 49.36M |
| October 12, 2026 | 46.42M |
| October 09, 2026 | 46.61M |
| October 08, 2026 | 50.09M |
| October 07, 2026 | 51.93M |
| October 06, 2026 | 55.60M |
| October 05, 2026 | 54.80M |
| October 02, 2026 | 55.17M |
| October 01, 2026 | 56.51M |
| September 30, 2026 | 62.14M |
| September 29, 2026 | 53.80M |
| September 28, 2026 | 53.44M |
| September 25, 2026 | 49.89M |
| September 24, 2026 | 49.83M |
| September 23, 2026 | 50.20M |
| September 22, 2026 | 54.47M |
| September 21, 2026 | 51.97M |
| September 18, 2026 | 48.61M |
| September 17, 2026 | 56.00M |
| September 16, 2026 | 50.01M |
| September 15, 2026 | 46.47M |
| September 14, 2026 | 48.43M |
| September 11, 2026 | 48.61M |
| September 10, 2026 | 52.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 21.63B |
| Arbutus Biopharma Corp. | 476.87M |
| ACADIA Pharmaceuticals, Inc. | 2.135B |
| Alnylam Pharmaceuticals, Inc. | 19.20B |
| Anika Therapeutics, Inc. | 159.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.07M |
| Revenue (Quarterly) | 38.43M |
| Total Expenses (Quarterly) | 86.50M |
| EPS Diluted (Quarterly) | -7.362 |
| Gross Profit Margin (Quarterly) | 99.41% |
| Profit Margin (Quarterly) | -125.1% |
| Earnings Yield | -412.8% |
| Normalized Earnings Yield | -436.78 |